tasisulam

Small moleculeexperimental

Clinical trial activity

13 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
6
Phase 3
1
Phase 4
0

Earliest trial started Sep 1, 2006 (NCT00363766)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl
Mol. weight
415.12 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ly573636
  • ly573636
  • ly573636
  • ly573636
  • ly 573636
  • ly-573636
  • ly573636 sodium
  • n-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
  • tasisulam
  • tasisulam
  • tasisulam
  • tasisulam

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01209832Phase 1Sep 1, 2010Eli Lilly
NCT01185548Phase 1Jul 1, 2010Eli Lilly
NCT01006252Phase 3Dec 1, 2009Eli Lilly
NCT00992225Phase 2Sep 1, 2009Eli Lilly
NCT01214668Phase 1Jan 1, 2009Eli Lilly
NCT00718159Phase 1Aug 1, 2008Eli Lilly
NCT01284335Phase 1Jul 1, 2008Eli Lilly
NCT01258348Phase 1Jul 1, 2008Eli Lilly
NCT01215916Phase 1Feb 1, 2008Eli Lilly
NCT00490451Phase 2Aug 1, 2007Eli Lilly
NCT00428610Phase 2Feb 1, 2007Eli Lilly
NCT00383292Phase 2Nov 1, 2006Eli Lilly
NCT00363766Phase 2Sep 1, 2006Eli Lilly
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit131332006
1 organizations
Page 1 / 1